<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00993629</url>
  </required_header>
  <id_info>
    <org_study_id>B7064-W</org_study_id>
    <nct_id>NCT00993629</nct_id>
  </id_info>
  <brief_title>Adjunctive Pregnenolone in Post-Traumatic Stress Disorder (PTSD) and Depression in Operations Enduring Freedom and Iraqi Freedom (OEF/OIF) Veterans</brief_title>
  <official_title>Adjunctive Pregnenolone in PTSD and Depression in OEF/OIF Veterans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>US Department of Veterans Affairs</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be an 8-week randomized, placebo-controlled clinical trial of pregnenolone&#xD;
      administered adjunctively to treatment as usual in PTSD and depression in OEF/OIF Veterans.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PTSD and depression are critical areas of immediate impact to Operation Enduring Freedom and&#xD;
      Operation Iraqi Freedom (OEF/OIF) Veterans. Current treatments for PTSD (which frequently&#xD;
      co-occurs with depression) remain limited, with many patients remaining symptomatic despite&#xD;
      single or combination administration of SSRIs, mood stabilizers, antipsychotics and&#xD;
      sedatives/hypnotics. In addition, many patients treated for depression remain symptomatic.&#xD;
      New interventions are thus urgently needed in PTSD with co-occurring depression to ensure&#xD;
      optimal functional outcomes for our Service members and their families.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    PI turned down funding.&#xD;
  </why_stopped>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinician Administered PTSD Scale (CAPS)</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Post-traumatic Stress Disorder</condition>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>adjunctive pregnenolone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>adjunctive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pregnenolone</intervention_name>
    <description>Administered adjunctively to &quot;treatment as usual&quot;</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>adjunctive placebo</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of PTSD,&#xD;
&#xD;
          -  diagnosis of MDD,&#xD;
&#xD;
          -  age 18-55,&#xD;
&#xD;
          -  no change in psychotropic medication for &gt;=4 weeks,&#xD;
&#xD;
          -  no anticipated need to to alter psychotropic medication for duration of study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unstable medical/neurological illness,&#xD;
&#xD;
          -  diagnosis of bipolar disorder, schizophrenia or other psychotic disorder,&#xD;
&#xD;
          -  cognitive disorder,&#xD;
&#xD;
          -  substance dependence,&#xD;
&#xD;
          -  positive urine drug screen at screening,&#xD;
&#xD;
          -  use of hormonal supplementation,&#xD;
&#xD;
          -  pregnancy/lactation,&#xD;
&#xD;
          -  female patients who are sexually active and not using acceptable non-hormonal birth&#xD;
             control,&#xD;
&#xD;
          -  initiation/change of psychotherapy within 3 months of randomization,&#xD;
&#xD;
          -  recent/current electroconvulsive therapy,&#xD;
&#xD;
          -  regular use of opiates/barbiturates/benzodiazepines&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Victoria M Payne, MD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Medical Center, Durham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Medical Center, Durham</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>October 7, 2009</study_first_submitted>
  <study_first_submitted_qc>October 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2009</study_first_posted>
  <last_update_submitted>October 23, 2014</last_update_submitted>
  <last_update_submitted_qc>October 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PTSD</keyword>
  <keyword>Depression</keyword>
  <keyword>Neurosteroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

